RUNX1 and myelodysplastic syndrome: Importantly, heterozygous pathogenic RUNX1 variants alone are insufficient to cause malignancy; secondary somatic events affecting RUNX1 or other hematologic malignancy-associated genes are required for progression to MDS, AML, or, more rarely, lymphoid malignancies (16).